Login to Your Account



Clinic roundup


Monday, February 24, 2014
Ignyta Inc., of San Diego, said preliminary results were presented from the ongoing phase I dose escalation portion of a phase I/II trial of RXDX-101, Ignyta’s oral tyrosine kinase inhibitor targeting solid tumor indications, at the International Association for the Study of Lung Cancer 14th Annual Targeted Therapies for the Treatment of Lung Cancer Meeting.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription